Skip to content

Study · Animal study (in vivo) · rat · 2003

10 results

The melanocortin agonist Melanotan-II reduces the orexigenic and adipogenic effects of neuropeptide Y (NPY) but does not affect the NPY-driven suppressive effects on the gonadotropic and somatotropic axes in the male rat.

Raposinho PD, White RB, Aubert ML

Journal of neuroendocrinology1 Feb 2003Cited by 38 (Europe PMC)

PMID12535159 (opens in a new tab)DOI10.1046/j.1365-2826.2003.00962.x (opens in a new tab)PepBankPUB-12535159
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In male rats, central MT-II infusion produced almost full anorexia for 1-2 days, then feeding gradually returned to normal despite continued infusion.

    In plain wordsIn rats given MTII by central infusion, eating almost stopped for 1-2 days, then gradually returned to normal.

    Peptide
    Melanotan II
    Outcome
    MixedFood intake during MT-II infusion
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    15 nmol/day · central infusion · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    MT-II produced almost full anorexia for 1-2 days but then feeding gradually returned to normal despite continued MT-II infusion.
    1 context sentence
    Summary · context
    We evaluated the effects of a 7-day central infusion of MT-II (15 nmol/day) given either alone or in association with NPY (5 nmol/day) in male Sprague-Dawley rats.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In male rats, co-infusion of MT-II with NPY gave an initial anorectic episode, then kept feeding at upper normal levels, cancelling the NPY-driven hyperphagia.

    In plain wordsIn rats, MT-II given with NPY cancelled the extra eating that NPY alone caused.

    Peptide
    Melanotan II
    Outcome
    DecreaseNPY-driven hyperphagia with MT-II co-infusion
    Study

    ratn: not reported in source

    Comparator
    NPY alone
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    15 nmol/day · central infusion · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    When coinfused with NPY, MT-II also produced the same initial anorectic episode but then maintained feeding to upper normal levels, thus cancelling the hyperphagia driven by NPY.
    1 context sentence
    Summary · context
    We evaluated the effects of a 7-day central infusion of MT-II (15 nmol/day) given either alone or in association with NPY (5 nmol/day) in male Sprague-Dawley rats.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In male rats, MT-II infusion reduced adiposity by a factor of two compared with pair-fed rats.

    In plain wordsIn rats, MT-II lowered body fat by half compared with pair-fed rats.

    Peptide
    Melanotan II
    Outcome
    DecreaseAdiposity versus pair-fed rats
    Study

    ratn: not reported in source

    Comparator
    Pair-fed rats
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    15 nmol/day · central infusion · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Whereas NPY infusion produced a doubling of fat pad weight, MT-II reduced adiposity by a factor of two compared to pair-fed rats, and vastly curtailed the NPY-driven increase in fat pad weight.
    1 context sentence
    Summary · context
    We evaluated the effects of a 7-day central infusion of MT-II (15 nmol/day) given either alone or in association with NPY (5 nmol/day) in male Sprague-Dawley rats.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In male rats, MT-II vastly curtailed the NPY-driven increase in fat pad weight.

    In plain wordsIn rats, MT-II strongly limited the fat gain that NPY alone caused.

    Peptide
    Melanotan II
    Outcome
    DecreaseNPY-driven increase in fat pad weight
    Study

    ratn: not reported in source

    Comparator
    NPY alone
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    15 nmol/day · central infusion · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Whereas NPY infusion produced a doubling of fat pad weight, MT-II reduced adiposity by a factor of two compared to pair-fed rats, and vastly curtailed the NPY-driven increase in fat pad weight.
    1 context sentence
    Summary · context
    We evaluated the effects of a 7-day central infusion of MT-II (15 nmol/day) given either alone or in association with NPY (5 nmol/day) in male Sprague-Dawley rats.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In male rats, MT-II infusion significantly curtailed the NPY-induced rise in insulin secretion.

    In plain wordsIn rats, MT-II reduced the rise in insulin that NPY alone caused.

    Peptide
    Melanotan II
    Outcome
    DecreaseNPY-induced rise in insulin
    Study

    ratn: not reported in source

    Comparator
    NPY alone
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    15 nmol/day · central infusion · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    MT-II infusion also significantly curtailed the NPY-induced rise in insulin and leptin secretions.
    1 context sentence
    Summary · context
    We evaluated the effects of a 7-day central infusion of MT-II (15 nmol/day) given either alone or in association with NPY (5 nmol/day) in male Sprague-Dawley rats.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In male rats, MT-II infusion significantly curtailed the NPY-induced rise in leptin secretion.

    In plain wordsIn rats, MT-II reduced the rise in leptin that NPY alone caused.

    Peptide
    Melanotan II
    Outcome
    DecreaseNPY-induced rise in leptin
    Study

    ratn: not reported in source

    Comparator
    NPY alone
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    15 nmol/day · central infusion · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    MT-II infusion also significantly curtailed the NPY-induced rise in insulin and leptin secretions.
    1 context sentence
    Summary · context
    We evaluated the effects of a 7-day central infusion of MT-II (15 nmol/day) given either alone or in association with NPY (5 nmol/day) in male Sprague-Dawley rats.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In male rats, co-infusion of MT-II did not reverse the NPY-driven inhibition of the gonadotropic axis.

    In plain wordsIn rats, MT-II did not undo the drop in reproductive hormone activity that NPY caused.

    Peptide
    Melanotan II
    Outcome
    No significant changeNPY-suppressed gonadotropic axis with MT-II co-infusion
    Study

    ratn: not reported in source

    Comparator
    NPY alone
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    15 nmol/day · central infusion · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    chronic NPY infusion strongly inhibited both the gonadotropic and somatotropic axes, and coinfusion of MT-II did not reverse these NPY-driven effects, in sharp contrast with that seen for the metabolic data.
    1 context sentence
    Summary · context
    We evaluated the effects of a 7-day central infusion of MT-II (15 nmol/day) given either alone or in association with NPY (5 nmol/day) in male Sprague-Dawley rats.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In male rats, co-infusion of MT-II did not reverse the NPY-driven inhibition of the somatotropic axis.

    In plain wordsIn rats, MT-II did not undo the drop in growth hormone activity that NPY caused.

    Peptide
    Melanotan II
    Outcome
    No significant changeNPY-suppressed somatotropic axis with MT-II co-infusion
    Study

    ratn: not reported in source

    Comparator
    NPY alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    15 nmol/day · central infusion · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    chronic NPY infusion strongly inhibited both the gonadotropic and somatotropic axes, and coinfusion of MT-II did not reverse these NPY-driven effects, in sharp contrast with that seen for the metabolic data.
    1 context sentence
    Summary · context
    We evaluated the effects of a 7-day central infusion of MT-II (15 nmol/day) given either alone or in association with NPY (5 nmol/day) in male Sprague-Dawley rats.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In male rats, MT-II infusion alone had little effect on the gonadotropic axis.

    In plain wordsIn rats, MT-II alone had little effect on reproductive hormone activity.

    Peptide
    Melanotan II
    Outcome
    No significant changeGonadotropic axis with MT-II alone
    Study

    ratn: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    15 nmol/day · central infusion · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    MT-II infusion alone had little effect on these axes.
    1 context sentence
    Summary · context
    We evaluated the effects of a 7-day central infusion of MT-II (15 nmol/day) given either alone or in association with NPY (5 nmol/day) in male Sprague-Dawley rats.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In male rats, MT-II infusion alone had little effect on the somatotropic axis.

    In plain wordsIn rats, MT-II alone had little effect on growth hormone activity.

    Peptide
    Melanotan II
    Outcome
    No significant changeSomatotropic axis with MT-II alone
    Study

    ratn: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    15 nmol/day · central infusion · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    MT-II infusion alone had little effect on these axes.
    1 context sentence
    Summary · context
    We evaluated the effects of a 7-day central infusion of MT-II (15 nmol/day) given either alone or in association with NPY (5 nmol/day) in male Sprague-Dawley rats.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.